# AI Proteins

> AI Proteins is a Boston biotechnology company designing de novo miniproteins as potential medicines. Its AI-guided, automated design-make-test-learn platform supports an internal preclinical pipeline and research collaborations, including an option agreement with Bristol Myers Squibb.

- **Founded:** 2021
- **Headquarters:** Boston, United States
- **Founders:** Chris Bahl (Founder and CEO)
- **Products:** De novo miniprotein discovery platform, Internal therapeutic pipeline, Partner discovery programs
- **Notable:** Designed miniprotein binders against more than 150 targets, according to the company., Reported multiple in vivo proof-of-concept results across internal programs., Signed a Bristol Myers Squibb research and option agreement with up to $400 million in potential milestones, plus royalties.

## Products & services

- **De novo miniprotein discovery platform** — Generative design, automated production, experimental validation and AWESSM-guided optimization of synthetic miniproteins.
- **Internal therapeutic pipeline** — Preclinical programs include TNFR1 antagonism for inflammation and targeted radiotherapy approaches for oncology.
- **Partner discovery programs** — Target-specific miniprotein discovery and optimization for biopharmaceutical collaborators, including Bristol Myers Squibb.

## Achievements

- Designed miniprotein binders against more than 150 targets, according to the company.
- Reported multiple in vivo proof-of-concept results across internal programs.
- Signed a Bristol Myers Squibb research and option agreement with up to $400 million in potential milestones, plus royalties.
- Won the 2024 Falling Walls Venture science startup competition.

## Latest updates

- **2025-11** — Closed $41.5 million Series A and announced a hub-and-spoke structure for focused program subsidiaries.
- **2025-08** — Appointed founding team member James Bowman as chief technology officer.
- **2025-02** — Appointed Philip E. Brandish as chief development officer.
- **2025-01** — Chris Bahl became CEO; the company began a University of Missouri radioligand research collaboration.

## Links

- Website: https://www.aiproteins.com
- LinkedIn: https://www.linkedin.com/company/aiproteins/
- Twitter/X: https://twitter.com/AI_Proteins
- GitHub: https://github.com/aiproteins
- Bluesky: https://bsky.app/profile/aiproteins.com

---

Profile page: https://yespress.io/ai-proteins
Published by YesPress — https://yespress.io
Last updated: 2026-09-29